The Food and Drug Administration is overseeing and validating the voluntary recall initiated by Nestlé Philippines involving select batches of NAN OPTIPRO and NANKID OPTIPRO infant formula products following a potential safety and quality concern.
In a statement, the FDA said the recall was prompted by a reported incident involving a raw material supplied to the manufacturer.
“The FDA informs the public that it is actively overseeing and validating the voluntary recall initiated by Nestlé Philippines involving specific batches of NAN OPTIPRO and NANKID OPTIPRO infant formula products as a precautionary measure following the identification of a potential safety and quality concern,” the agency said.
The FDA clarified that there are currently no established food safety or regulatory limits on the raw material identified and that an investigation is ongoing to determine the scope of the issue and assess any possible safety implications.
The agency said it is coordinating closely with Nestlé Philippines to verify the affected batches and ensure the prompt removal of recalled products from physical and online retail outlets. The FDA is also conducting distribution and communication checks to confirm that recall measures are implemented across the supply chain.
“At this time, the FDA has not received any reports of illness or adverse events associated with the recalled products,” the agency said, adding that it supports the precautionary recall to protect public health, “especially infants and young children.”
The FDA advised consumers, including parents and caregivers in Palawan, to check product batch numbers, immediately stop using affected products and follow recall instructions issued by the manufacturer.
“An official FDA Advisory for the guidance of the general public will be issued to provide further information and updates,” the agency said.
The FDA said it will continue post market surveillance, inspections and product assessments to ensure that regulated products meet safety and quality standards.
“Any significant findings will be promptly disclosed in the interest of transparency and consumer protection,” it added.
The agency reiterated its mandate to ensure that all regulated health products in the market are safe, of good quality and compliant with existing laws and regulations.
